187 related articles for article (PubMed ID: 38753747)
21. Theranostic in Nuclear Medicine - The paradigm of NET.
Giammarile F
Hell J Nucl Med; 2023; 26 Suppl():42-43. PubMed ID: 37658562
[TBL] [Abstract][Full Text] [Related]
22. Copper radiopharmaceuticals for theranostic applications.
Ahmedova A; Todorov B; Burdzhiev N; Goze C
Eur J Med Chem; 2018 Sep; 157():1406-1425. PubMed ID: 30282317
[TBL] [Abstract][Full Text] [Related]
23. Nuclear medicine theranostics comes of age.
Herrmann K; Kraus BJ; Hadaschik B; Kunikowska J; van Poppel H; N'Dow J; Sartor O; Oyen WJG
Lancet Oncol; 2021 Nov; 22(11):1497-1498. PubMed ID: 34735807
[No Abstract] [Full Text] [Related]
24. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
Langbein T; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
[TBL] [Abstract][Full Text] [Related]
25. Theranostic Radiopharmaceuticals: A Universal Challenging Educational Paradigm in Nuclear Medicine.
Urbain JL; Scott AM; Lee ST; Buscombe J; Weston C; Hatazawa J; Kinuya S; Singh B; Haidar M; Ross A; Lamoureux F; Kunikowska J; Wadsak W; Dierckx R; Paez D; Giammarile F; Lee KH; O JH; Moshe M; Louw L; More S; Nadel H; Lee D; Wahl R
J Nucl Med; 2023 Jun; 64(6):986-991. PubMed ID: 37142302
[No Abstract] [Full Text] [Related]
26. Transforming Nuclear Medicine with Nanoradiopharmaceuticals.
Roy I; Krishnan S; Kabashin AV; Zavestovskaya IN; Prasad PN
ACS Nano; 2022 Apr; 16(4):5036-5061. PubMed ID: 35294165
[TBL] [Abstract][Full Text] [Related]
27. [PSMA-based theranostics for prostate cancer : From imaging to treatment].
Ilhan H; la Fougère C; Krause BJ
Urologe A; 2020 May; 59(5):617-625. PubMed ID: 32377764
[TBL] [Abstract][Full Text] [Related]
28. Highlights of the annual congress of the European Association of Nuclear Medicine, Amsterdam 2003.
Signore A
Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):439-58. PubMed ID: 14747960
[No Abstract] [Full Text] [Related]
29. Theranostics - a sure cure for cancer after 100 years?
Song Y; Zou J; Castellanos EA; Matsuura N; Ronald JA; Shuhendler A; Weber WA; Gilad AA; Müller C; Witney TH; Chen X
Theranostics; 2024; 14(6):2464-2488. PubMed ID: 38646648
[TBL] [Abstract][Full Text] [Related]
30. Theranostics and metabolotheranostics for precision medicine in oncology.
Bhujwalla ZM; Kakkad S; Chen Z; Jin J; Hapuarachchige S; Artemov D; Penet MF
J Magn Reson; 2018 Jun; 291():141-151. PubMed ID: 29705040
[TBL] [Abstract][Full Text] [Related]
31. Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer.
Plichta KA; Graves SA; Buatti JM
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829977
[TBL] [Abstract][Full Text] [Related]
32. Activatable Theranostics.
Huang P
Curr Med Chem; 2019; 26(8):1310. PubMed ID: 31189459
[No Abstract] [Full Text] [Related]
33. Metal-derived nanoparticles in tumor theranostics: Potential and limitations.
Kuchur OA; Tsymbal SA; Shestovskaya MV; Serov NS; Dukhinova MS; Shtil AA
J Inorg Biochem; 2020 Aug; 209():111117. PubMed ID: 32473483
[TBL] [Abstract][Full Text] [Related]
34. The future of nuclear medicine imaging of neuroendocrine tumors: on a clear day one might see forever...
Bodei L; Kidd M; Prasad V; Baum RP; Drozdov I; Modlin IM
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2189-93. PubMed ID: 25047018
[No Abstract] [Full Text] [Related]
35. Re-thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals.
Notni J; Wester HJ
J Labelled Comp Radiopharm; 2018 Mar; 61(3):141-153. PubMed ID: 29143368
[TBL] [Abstract][Full Text] [Related]
36. Training Requirements for Theranostics: A Unique Opportunity for Collaboration.
Graham MM; Buatti JM
J Nucl Med; 2019 Sep; 60(9):1205-1206. PubMed ID: 30954946
[No Abstract] [Full Text] [Related]
37. Prussian blue nanoparticles and their analogues for application to cancer theranostics.
Patra CR
Nanomedicine (Lond); 2016 Mar; 11(6):569-72. PubMed ID: 26911239
[No Abstract] [Full Text] [Related]
38. Nanoparticle Diagnostics and Theranostics in the Clinic.
Pallares RM; Mottaghy FM; Schulz V; Kiessling F; Lammers T
J Nucl Med; 2022 Dec; 63(12):1802-1808. PubMed ID: 36302654
[TBL] [Abstract][Full Text] [Related]
39. Molecular imaging and therapy in nuclear medicine.
Bouziotis P
Curr Top Med Chem; 2012; 12(23):2641. PubMed ID: 23339759
[No Abstract] [Full Text] [Related]
40. All-in-One Nanomedicine: Multifunctional Single-Component Nanoparticles for Cancer Theranostics.
Cai Y; Chen X; Si J; Mou X; Dong X
Small; 2021 Dec; 17(52):e2103072. PubMed ID: 34561968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
